Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)
Purification
TAB1 Antibody is affinity chromatography purified via peptide column.
Immunogen
TAB1 antibody was raised against a synthetic peptide corresponding to 13 amino acids in the center of human TAB1. The immunogen is located within amino acids 220 - 270 of TAB1.
TAB1
Reactivity: Human
WB
Host: Mouse
Polyclonal
unconjugated
Application Notes
TAB1 antibody can be used for the detection of TAB1 by Western blot at 0.5 to 2 μ,g/mL. Antibody can also be used for immunocytochemistry starting at 1 μ,g/mL. For immunofluorescence start at 2 μ,g/mL.
Antibody validated: Western Blot in mouse samples, Immunocytochemistry in human samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
TAB1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
TAB1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
TAB1
(TGF-beta Activated Kinase 1/MAP3K7 Binding Protein 1 (TAB1))
TAB1 Antibody: TAB1 was identified as a regulator of the MAP kinase kinase kinase TAK1/MAP3K7, which is known to mediate various intracellular signaling pathways, such as those induced by TGF-beta and members of the Toll-IL-1R (TIR) superfamily, thus acting as an intermediate in both proliferative and innate and adaptive immune responses. This protein, together with either TAB2 or TAB3, activates TAK1 kinase in response to upstream signals. It has been shown that the C-terminal portion of TAB1 is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF-beta, demonstrating how this protein can function as a mediator between TGF-beta receptors and TAK1.